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Abstract
Background: Assessment of eye irritation hazard has long been a core requirement in any chemical legislation.
Nevertheless, publications focussing on the eye damaging potential of nanomaterials are scarce. Traditionally, eye
irritation testing was performed using rabbits. The OECD Test Guideline 437 Bovine Corneal Opacity and Permeability
(BCOP) test method allows determining severely irritating substances without animals, and the recently adopted
OECD Test Guideline 492 Reconstructed human cornea-like epithelium test method allows identifying chemicals that
neither induce eye irritation nor serious eye damage. For substances applicable to these tests, huge progress has
been made in replacing animal testing.
Methods: The in vitro eye irritation potential of 20 nanosized and 3 non-nanosized materials was investigated in a
2-tier EpiOcular™ Eye Irritation Test (EpiOcular™-EIT) and BCOP testing strategy including histopathology of the
bovine corneas. Furthermore, applicability of the testing strategy for nanomaterials was assessed. Test materials
encompassed OECD representative nanomaterials (metals (Ag), metal oxides (ZnO, TiO2, CeO2), amorphous SiO2
and MWCNTs), three organic pigments, quartz, and talc.
Results: None of the dry-powder nanomaterials elicited eye irritation in either the EpiOcular™-EIT or the BCOP
assay. Likewise, an amorphous SiO2 nanomaterial that was supplied as suspension was tested negative in both
assays. By contrast, in the EpiOcular™-EIT, the silver nanomaterial that was supplied as dispersion was tested
positive, whereas its surfactant-containing dispersant was borderline to negative. In the BCOP assay, the silver
nanomaterial elicited highly variable results and dark-brown patches remained on the corneal surface, whereas the
results for its dispersant alone were borderline to positive, which was assessed as inconclusive due to high
inter-assay variability.
Conclusion: The present study points to the low eye irritation potential of a spectrum of nanomaterials, which is
consistent with available in vivo data for the same test materials or for nanosized or bulk materials of the same
composition.
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Background
Throughout the world, assessment of potential eye irrita-
tion hazard has long been a core requirement in chem-
ical legislation. For instance, information on this
endpoint is mandatory for all (nanosized or conven-
tional) substances in accordance with the European
Regulation on the Registration, Evaluation, Authorisa-
tion, and Restriction of Chemicals (REACH [1]). To fulfil
global legislative requirements, testing protocols adopted
by the Organisation for Economic Co-operation and De-
velopment (OECD) are needed. As a result, the majority
of existing assessments are based on animal tests (i.e.
OECD Test Guideline (TG) 405 [2]).
With the adoption of the TG for the Bovine Corneal
Opacity and Permeability (BCOP) test method for identi-
fying ocular corrosives and severe irritants (OECD TG
437) in 2009, it became possible to register severely irri-
tating substances (i.e. ‘Category 1’ substances; cf. Infor-
mation box on hazard categorization) without the need
for animal testing. In 2013, the TG for the BCOP assay
was revised to further allow identifying substances not
requiring classification for eye irritation or serious eye
damage, i.e. ‘Non-category’ substances if the irritation
scores are below a certain threshold limit [3]. Finally,
with the recent adoption of the TG for the Reconstructed
human cornea-like epithelium test method for identifying
chemicals not requiring classification and labelling for
eye irritation or serious eye damage (OECD TG 492 [4])
on 28 July 2015, during the preparation of the present
article, huge progress has been made in replacing animal
testing for the endpoint ‘eye irritation’.
Notwithstanding the human health relevance of this
endpoint, publications focussing on the eye damaging
potential of nanomaterials (NMs) are scarce. The major-
ity of publications addressing their toxicological effects,
either in vivo or in vitro, report investigations on re-
spiratory tract effects, since for most NMs, inhalation is
the predominant route of exposure provided that they
are released either during production or use [7, 8]. Most
of the available studies on eye irritation evaluated the
local toxicity of NMs developed for intentional applica-
tion to the eye, e.g. as ocular drug delivery devices, a
topic reviewed by Prow [9]. Frequently, the safety of
such devices is assessed in in vivo studies using rabbits
[10–15]. As regards in vitro eye irritation testing of
nanosized ocular drug carriers [16, 17], recently, Bhasker
et al. [18] evaluated the effects of nanoformulated bovine
lactoferrin or SurR9-C84A proteins on normal or
insulted ex vivo bovine cornea models observing eye-
irritating properties on neither model. Generally, the eye
irritation potential of ocular drug carriers appears to in-
crease with increasing lipophilicity as was assessed using
a set of different non-nanosized lipoamino acids in saline
solution [19].
Even fewer scientific publications are available ad-
dressing the eye irritation potential of NMs that are not
intended for topical ocular application: In an in vivo
rabbit eye irritation study performed in accordance with
the OECD TG 405, 21 % anatase / 79 % rutile TiO2
(140 nm in water; Dynamic Light Scattering (DLS)) pro-
duced reversible conjunctival redness [20]. Instilling
5,000 ppm self-prepared precipitated colloidal Ag NMs
(10-20 nm) in aqueous suspension into the eyes of
guinea pigs produced eye irritation that was fully reversible
within 24 h [21]. In humans, silver particles from silver-
containing antibacterial agents were found to deposit in the
cornea [22]. Kishore et al. [23] reported two differently
sized multi-walled carbon nanotubes (MWCNTs) to elicit
reversible conjunctival redness and discharge in the rabbit
eye (MWCNT 1: 5–8 μm length; 3–8 nm inside diameter;
140 ± 30 nm outside diameter; MWCNT 2: 1–10 μm
length; 2–6 nm inside diameter; 10–15 nm outside diam-
eter; both MWCNTs forming compact aggregates). While
the limited data available in the published literature
suggest that NM eye irritancy potential might gener-
ally be low, there are currently no studies allowing
the comparison of ocular effects induced by different
types of NMs.
Therefore, in the present study the in vitro eye ir-
ritation potential of a broad spectrum of altogether
20 nanosized and three non-nanosized materials was
investigated. Sixteen NMs were OECD representative
NMs that are metals (Ag), metal oxides (ZnO, TiO2,
CeO2), precipitated and pyrogenic amorphous SiO2
and MWCNTs. These NMs have been coded in the
list of the OECD Sponsorship Program for the Test-
ing of Manufactured Nanomaterials (http://www.oecd.
org/science/nanosafety/; accessed 7 April 2016). Since
Ag NM-300 K was provided as dispersion, also its dis-
persant alone, i.e. Ag NM-300 K DIS, was assessed (NM-x
numbers refer to the respective codes of the OECD repre-
sentative NMs). Since all further OECD representative
Information box - Hazard categorization of substances causing
local ocular toxicity
The European Regulation on the Classification, Labelling and
Packaging (CLP) of Substances and Mixtures [5] distinguishes two
categories:
- Category 1 for substances causing serious or irreversible eye damage
(‘corrosion’) that persists within 21 days post-exposure;
- Category 2 for those inducing reversible eye damage (‘irritation’).
Specifically, Category 2 is assigned if a substance produces - at least in 2
of 3 tested animals - a positive response of corneal opacity ≥1 and/or
iritis ≥1 and/or conjunctival redness ≥2 and/or conjunctival edema
(chemosis) ≥2 (calculated as the mean scores following grading at 24,
48 and 72 h after treatment) and all effects are fully reversible within
21 days [5].
The United Nations Globally Harmonised System (UN GHS [6]) further
foresees differentiating between
- Category 2A (irritating to the eye)
- Category 2B (mildly irritating to the eye), if effects are fully reversible
within 7 days of substance application.
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NMs were provided as powder, Levasil® 200, a precipitated
amorphous SiO2 that is provided as 40 % suspension (in
the following: aSiO2-susp), was included as further test
material to evaluate whether the ‘as supplied’ preparation
of a test material affects eye irritation potential or potency.
Likewise, non-nanosized quartz dust DQ12 was taken up
into the study, since crystalline SiO2 is known to generally
have a higher toxic potential than amorphous SiO2. Add-
itionally, three organic pigments that fall under the EU
recommendation on the definition of nanomaterials [24]
representing three different chemical classes, i.e. Pigment
Red 57:1, Pigment Yellow 95, and Pigment Black 32, were
included. These pigments were selected based upon avail-
ability of physico-chemical characterisation data and Good
Laboratory Practice-compliant animal data. To date, no
organic pigment has been classified as an eye irritant.
Otherwise it would have been included in the present
study. Finally, non-nanosized talc, the historical negative
control for in vivo eye irritation testing, was added to the
spectrum of test materials.
All 23 test materials were submitted to a 2-tier non-
animal testing strategy composed of the EpiOcular™ Eye
Irritation Test (EpiOcular™-EIT; OECD TG 492) and the
Bovine Corneal Opacity and Permeability (BCOP; OECD
TG 437) assay including histopathological evaluation of
the cornea [25, 26]. Thereby, the present study further
aimed at investigating the usefulness of this testing strat-
egy for the hazard assessment and categorization of
NMs. Of note, while histopathological evaluation of the
cornea has not yet been incorporated in OECD TG 437,
the OECD has published a guidance document to pro-
mote such assessments [27]. The outcome of the in vitro
2-tier testing was compared to available in vivo data
from eye irritation studies performed in accordance with
OECD TG 405 (or comparable methods). For the three
organic pigments, in-house data from earlier in vivo eye
irritation studies were available. For the other test mate-
rials, in vivo eye irritation data and classifications from
corresponding REACH dossiers were evaluated. No new
in vivo studies were performed for the purpose of the
present study.
Whereas data from in vitro eye irritation tests may be
used to fulfil the REACH standard information require-
ments for substances with low annual production vol-
umes, before the adoption of OECD TG 492 in July
2015, the in vivo rabbit eye irritation test was generally
prescribed for all substances with annual volumes ex-
ceeding 10 tonnes [1] unless the existing in vitro data
were suitable for hazard classification and labelling. The
animal welfare concerns and scientific limitations of this
so-called ‘Draize test’ have been widely recognized for
many years [28]. However, in spite of numerous research
efforts [29], on the global scale its full replacement in ac-
cordance with the 3Rs principle [30, 31] is outstanding.
The BCOP assay (OECD TG 437), as partial replace-
ment method, allows the identification of ‘Non-category’
substances and ‘Category 1’ substances inducing serious
or irreversible eye damage. To date, there is no non-
animal test method allowing direct ‘Category 2’ classifi-
cation for eye irritation having achieved regulatory
acceptance. However, human cornea-like three-
dimensional (3D) reconstructed tissue models are prom-
ising in vitro models to distinguish ‘Non-category’ sub-
stances from ‘Category 1 or 2’ substances eliciting
corrosive or irritating effects [25, 32, 33]. An example
for such an assay is the EpiOcular™-EIT. It uses the
cornea-like non-keratinized tissue construct EpiOcular™
(MatTek Corp., USA) that is composed of normal hu-
man epidermal keratinocytes obtained from individual
donors. The model is cultured in proprietary serum-free
culture medium which induces corneal differentiation
and formation of the organotypic cornea-like model.
This three dimensional tissue consists of highly orga-
nized cell layers and exhibits barrier properties similar
to the normal in vivo corneal epithelium [32]. Tissue
destruction is determined by formazan reduction after
incubation with the tetrazolium salt 3-[4,5-dimethyl-
thiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT),
which reflects impaired mitochondrial dehydrogenase
activity.
The concept of combining methods to identify ocular
non-irritants and substances causing serious eye damage
to cover the full spectrum of eye irritation has previously
been described by Scott et al. [34], and the specific com-
bination of the EpiOcular™-EIT and the BCOP assay has
been submitted to an in-house validation study in the
authors’ laboratory [25]. Accordingly, with the adoption
of OECD TG 492, substances applicable to the two in
vitro test methods (i.e. the EpiOcular™-EIT and the
BCOP assay) should no longer require animal testing,
since ‘Category 2’ substances may be assessed indirectly:
In the 2-tier ‘bottom up’ testing strategy we suggest, the
EpiOcular™-EIT is performed in Tier 1 to distinguish
‘Category 1 or 2’ from ‘Non-category’ substances. In Tier
2, the BCOP assay is conducted to identify ‘Category 1’
substances from within the set of ‘Category 1 or 2’ sub-
stances identified in Tier 1. All substances that are not
identified as ‘Category 1’ in the BCOP assay in Tier 2
are classified as ‘Category 2’. By contrast, in a ‘top down’
approach, a substance considered a severe ocular irritant
would undergo the BCOP assay first, and if the result
would indicate that the substance is not ‘Category 1’
after all, it would undergo the EpiOcular™-EIT [25, 34].
However, also in the light of the newly adopted OECD
TG 492 [4], the European Chemicals Agency (ECHA)
holds a different view on the comprehensiveness of in
vitro testing. In the October 2015 version of the ECHA
guidance on endpoint-specific information requirements,
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a footnote in the section on serious eye damage/eye
irritation states: Please note that the information re-
quirements in REACH Annexes VII and VIII [i.e. the
standard information requirements for substances
imported or manufactured at production volumes of 1
or 10 tons or more, respectively] in relation to skin
corrosion/irritation and serious eye damage/eye irrita-
tion are currently under revision. This revision is ex-
pected to strengthen the role of in vitro methods and
to remove the standard information requirement for
an in vivo study at the Annex VIII level. As a conse-
quence, once the new REACH Annexes come into
force, an in vivo study would only be required where
a substance falls outside of the applicability domain
of the available in vitro methods or the results ob-
tained from such methods would not allow a conclu-
sive decision on (non-) classification and risk
assessment [35].
To the best of the authors’ knowledge, to date,
there are no publications reporting the in vitro as-
sessment of NMs intended for non-medicinal appli-
cations in the BCOP assay (OECD TG 437) or the
EpiOcular™-EIT (OECD TG 492). In accordance with
the 3R principle to refine, reduce and eventually re-
place animal tests [30] in the present study, the 2-
tier EpiOcular™- BCOP eye irritation testing strategy
was applied to assess the eye irritation potential of
the nanosized and non-nanosized test materials.
Therefore, the present study, submitting a broad
panel of extensively characterized NMs to in vitro
eye irritation and corrosion testing, not only aimed
at comparing the eye irritancy potential of these ma-
terials. In the light of the view of the OECD Working
Party on Manufactured Nanomaterials (WPMN) that
modifications to address the NM specificities of existing
OECD TGs [36] may be required, this study further
served to provide a first understanding on the applicability
of these two OECD TGs for the testing of NMs.
Methods
Test materials and particle characterisation
The 16 OECD representative NMs were supplied by
the European Commission’s Joint Research Centre
(Italy). They comprised six different TiO2 (anatase
NM-100, NM-101, NM-102; rutile NM-103, NM-104;
and rutile-anatase NM-105), uncoated (NM-110) and
coated (NM-111) ZnO, amorphous SiO2 produced by pre-
cipitation (NM-200) and by thermal process (NM-203),
uncoated CeO2 produced by precipitation (NM-211,
NM-212), monodispersed Ag produced by precipitation
(NM-300 K), and three MWCNTs of different lengths and
diameters (NM-400, NM-401, NM-402). All OECD repre-
sentative NMs were provided as powder, except for Ag
NM-300 K, which was provided in dispersion to prevent
its spontaneous oxidation in air. The Ag NM-300 K dis-
persant is an aqueous solution containing the capping
agents polyoxyethylene glycerol trioleate and polyoxy
ethylene-(20) sorbitan mono-laurate (Tween 20). This dis-
persant was included as a further, 17th (non-nanosized)
test material (NM-300 K DIS) to verify whether possible
effects induced by Ag NM-300 K were caused by the silver
or by its dispersant.
aSiO2-susp was supplied by AkzoNobel AB (Sweden)
and quartz dust DQ 12 by Doerentrup Quarz GmbH
(Germany). Talc was purchased from a local retailer, and
the three organic pigment samples of commercial grade
were provided by BASF SE.
Table 1 presents details of the intrinsic material prop-
erties of the test materials as well as the eye irritation
classifications from corresponding REACH dossiers (www.
echa.europa.eu/information-on-chemicals; accessed 7
April 2016). For Pigment Red 57:1, a total number of 13 in
vivo studies were identified during the preparation of
the REACH registration dossier. Pigment Yellow 95
and Pigment Black 32 had each been tested in house
in a Good Laboratory Practice-compliant in vivo study
(OECD TG 405).
The particle sizes of the OECD representative NMs
suspended in water (as they were prepared for applica-
tion in the BCOP assay; albeit excluding ZnO NM-111
and MWCNT NM-401 and NM-402) as well as details
on their water solubility are presented in Table 2. Par-
ticle sizes in water were determined by two complemen-
tary techniques, i.e. Analytical Ultracentrifugation (AUC)
and Laser Diffraction (LD). AUC relies on the time- and
space-resolved observation of sedimentation processes
and allows quantifying the fractions of the total dose
that are dispersed to diameters <100 nm and <1000 nm,
respectively. LD relies on the optical observation of the
diffraction and scattering of light, and provides the me-
dian diameter (LD D50) of the agglomerate fraction. LD,
however, is not reliable to detect dispersed nanoparticles.
Therefore, in the present study, prevalence was given to
AUC to determine which NMs were dispersed with
significant fractions below 100 nm. If results from the
AUC indicate that even the size interval up to
1000 nm only contains a smaller part (i.e. <50 %) of
the total dose of a given NM, this NM is strongly ag-
glomerated with certainty. In these cases, the LD D50
values are most likely reliable representations of the
average agglomerate particle size. If, however, results
from the AUC indicate that the size interval up to
1000 nm contributes considerably to the total dose,
the LD D50 values have to be evaluated with caution,
since they will not represent both small and large
particles.
For further details on the material properties of the 16
OECD representative NMs, cf. Sauer et al. [37, 38].
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Table 1 Intrinsic material properties of the test substances (for the OECD representative NMs, as provided by the supplier a)
OECD no./substance name Test material Physical state/form of production Purity (%), impurities Particle size (nm) and shape SSA (BET; m2/g) Classification ‘serious eye damage/eye
irritation’ b (CAS No./EC List No.)
NM-100 TiO2 pigmentary Anatase, uncoated >98.5 TEM: 42–90 10 Conclusive, but not sufficient for
classification (CAS No. 13463-67-7)
NM-101 TiO2 Anatase, uncoated 91.7 8, XRD: 6 320
NM-102 TiO2 Anatase, uncoated 96.0 22, XRD: 20 90
NM-103 TiO2 Rutile, ultrafine, hydrophobic 89.0; Al2O3: 6.2 % 20, XRD: 20 60
NM-104 TiO2 Rutile, ultrafine, hydrophilic 89.8; Al2O3: 6.2 % 20, XRD: 20 60
NM-105 TiO2 Rutile-anatase, uncoated > 99 21, XRD: 22 61
NM-110 ZnO Uncoated, white powder > 99 XRD: 41.5, spherical 13 ZnO nano: Conclusive, but not
sufficient for classification
(CAS No. 1314-13-2)NM-111 ZnO Coated with 1–4 % triethoxycaprylyl
silane, white powder
96–99 XRD: 33.8, spherical 16
NM-200 Amorphous SiO2 Produced by precipitation,
white powder
96.5 TEM: 20, spherical 230 Amorphous fumed silica and
precipitated silica gel: Conclusive,
but not sufficient for classification
(CAS No. 7631-86-9)NM-203 Amorphous SiO2 Produced by thermal process,
white powder
- TEM: 20, spherical, irregular 226
aSiO2-susp Amorphous SiO2 Synthesis by means of a growth
process from an aqueous solution
with dissociated molecular
silicic acid, opalescent suspension
>99 % TEM: 15 200
Quartz dust DQ12 Crystalline SiO2 Powder 87 %; rest: amorphous
SiO2, 0.2 % Al2O3;
0.03 % Fe2O3
89, hexagonal 5.9
NM-211 CeO2 Uncoated, produced by precipitation,
yellowish powder
> 95 XRD: 10.3, cubic 66 Bulk cerium dioxide: Conclusive,
but not sufficient for classification
(CAS No. 1306-38-3)
NM-212 CeO2 Uncoated, produced by precipitation,
yellowish powder
> 99.5 XRD: 33, cubic 28
NM-300 K Silver < 20 nm Produced by chemical precipitation
of AgNO3, monodispersed with
capping agents (cf. NM-300 K DIS);
silver content: 10.16 % w/w, very
viscous, concentrate orange-brown,
yellow in dilution
10 TEM: 15, colloidal, spherical Not available Silver (≥ 99.9 % Ag in nano form;
median particle size <100 nm):
Conclusive, but not sufficient for
classification (CAS No. 7440-22-4)
NM-300 K DIS Ag dispersant Aqueous solution containing the
capping agents: 4 % each of
polyoxyethylene glycerol trioleate
and polyoxyethylene (20) sorbitan
mono-laurate (Tween 20), very viscous
Tween 20 (CAS No. 9005-64-5)
non-irritant (OECD TG 437)
NM-400 MWCNT Specialty graphite, produced by CCVD,
at 20 °C and 1013 hPa: solid powder,
black odourless, insoluble in water
or organic solvent, surface charge:
NA, conductive
> 90; impurities:
< 10 % metal oxide
TEM: Ø 9.5, 1.5 μm length,
short, thin, tangled,
concentric tubes
280 Conclusive, but not sufficient for












Table 1 Intrinsic material properties of the test substances (for the OECD representative NMs, as provided by the supplier a) (Continued)
NM-401 MWCNT Specialty graphite, produced by
CCVD, at 20 °C and 1013 hPa: solid
powder, black odourless, insoluble
in water or organic solvent, surface
charge: NA, conductive
> 95, impurities:
< 5 % metal
oxides
TEM: Ø 10 - 30, 5 - 15 μm
length, short, thin, tangled,
concentric tubes
300
NM-402 MWCNT Specialty graphite, produced by
CCVD, at 20 °C and 1013 hPa: solid
powder, black odourless, insoluble
in water or organic solvent, surface
charge: NA, conductive
> 90, impurities:
< 10 % metal
oxides
TEM: Ø 5 - 15, 0.1 – 10 μm
length, short, thin, tangled
concentric tubes
250–300
Talc Powder >97 % non-nanosized non-nanosized Exempt from REACH registration
(CAS No. 14807-96-6)
Pigment Red 57:1 Red powder, insoluble in water and
octanol
>90 % TEM: polydisperse from
20 nm to 200 nm, mostly
irregular shapes of low
aspect ratio, some rods
59 Not irritating; 13 eye irritation studies
available, mostly comparable to
OECD TG 405, some GLP-compliant
(CAS No. 5281-04-9)
Pigment Yellow 95 Yellow Powder, insoluble in water
and octanol
>99 % TEM: mostly rods with aspect
ratios around 5, diameters
from 30 nm to 150 nm
57 Not irritating (OECD TG 405,
GLP-compliant)
Average score (24–72 h) for irritation:
0.0 for iris, 0.1 for corneal opacity
and conjunctival redness, and 0.3
for chemosis. (CAS No. 5280-80-8)
Pigment Black 32 Black Powder, insoluble in water
and octanol
>99 % TEM: mostly rods with aspect
ratios around 5, diameters
from 40 nm to 200 nm
39 Not irritating (OECD TG 405,
GLP-compliant)
Average score (24–72 h) for irritation:
0.0 for corneal opacity, iris and
chemosis and 0.3 for conjunctival
redness.(EC List No. 475-310-6)
Abbreviations: BET (Method of) Brunauer-Emmett-Teller, CCVD Catalytic chemical vapour deposition, GLP Good laboratory practice, MPS mean particle size, MWCNT Multi-walled carbon nanotube, PPS primary particle
size, SSA Specific surface area, TEM Transmission electron microscopy, XPS X-ray photoelectron spectroscopy, XRD X-ray diffraction
a For the OECD representative NMs, the European Commission’s Joint Research Centre, Ispra, Italy (Table parts referring to the 16 OECD representative NMs adapted from Sauer et al. [37]); for quartz dust DQ12,
Dörentrup Quarz GmbH & Co. KG, Germany, www.doerentrup.de (and further from Wohlleben et al. [70])
b Eye irritation classifications were retrieved from the corresponding REACH dossiers (www.echa.europa.eu/information-on-chemicals; accessed 7 April 2016). The formal phrase conclusive but not sufficient for














In the EpiOcular™-EIT, the test materials were applied
undiluted at amounts enabling to cover the entire tissue
surfaces. As a rule, this corresponded to 50 μL bulk
volume of the respective dry-powder test material or
50 μL of the liquid test materials Ag NM-300 K, Ag NM-
300 K DIS and aSiO2-susp. Only the MWCNTs had to be
applied at higher volumes to enable covering the entire
EpiOcular™ tissue surfaces (cf. Tables 3, 4 and 5 for the re-
spective NM masses applied).
BCOP assay
The OECD representative NMs that had been delivered
as powders (i.e. all except Ag NM-300 K and its dispers-
ant) were suspended in highly de-ionized water to achieve
final concentrations of 20 % (w/v) suspension and then
stirred with a magnetic stirrer. Additionally, TiO2 NM-
103, TiO2 NM-104, ZnO NM-110, and SiO2 NM-200
were stirred with a high-speed homogenizer (Ultra-
Turrax, Jahnke & Kunkel (IKA-Werke), Germany). All
test material suspensions were applied immediately after
preparation, and also during test material application, the
preparations were stirred with a magnetic stirrer to ensure
continued homogeneity. Suspensions of ZnO NM-111
and MWCNT NM-401 could not be prepared homoge-
neously. Hence, these test materials were applied un-
diluted, just as Ag NM-300 K, Ag NM-300 K DIS, aSiO2-
susp, quartz dust DQ12, the three organic pigments, and
talc were applied undiluted.
In vitro testing
EpiOcular™-EIT
The EpiOcular™-EIT was performed in two variants. The
16 OECD representative NMs and Ag NM-300 K DIS
were submitted to protocol variant 1, i.e. as described by
the supplier MatTek [39] and Harbell et al. [40]. aSiO2-
susp, quartz dust DQ12, the three organic pigments, and
talc were assessed in accordance with variant 2, i.e. as
described in the OECD TG 492. To ensure data compar-
ability, the dry-powder OECD representative NMs (ex-
cluding MWCNT NM-402) were additionally submitted
to variant 2. The two test protocol variants differ in re-
spect to the exposure and post-exposure immersion pe-
riods laid down for solid test materials. In the following,
both EpiOcular™-EIT protocol variants are presented
jointly specifically indicating the different exposure and
post-exposure durations.
Reagents, test systems, and technical equipment,
positive and negative controls The following reagents,
test systems and technical equipment were used: Spec-
trophotometer: Sunrise™ Absorbance Reader (Tecan
Group Ltd., Switzerland; measurement using a filter
wavelength of 570 nm without reference filter). MatTek
Corp. (USA) and MatTek In Vitro Life Science Labora-
tories (Slovakia) provided the following reagents and test
systems: EpiOcular™ OCL-200 kit (containing 24 OCL-
200 reconstructed cornea tissues, 0.6 cm2 surface area,
cultured in Millicells® with 1-cm diameter); Dulbecco‘s
modified eagle’s medium (DMEM; also purchased from
Table 2 Solid test substances a: Particle size in a 200 mg/mL suspension in water (applied in the BCOP assay), determined by
analytical ultracentrifugation (AUC) and laser diffraction (LD)




D50 [μm; LD] Water solubility
[AUC combined with ICP-MS / ICP-AES]
NM-100 TiO2 pigmentary 249
b 8.6 0.374
NM-101 TiO2 101 3.3 0.959
NM-102 TiO2 13.7 0.0 1.23
NM-103 TiO2 69.2 0.0 1.56
NM-104 TiO2 131 0.8 1.10
NM-105 TiO2 73.2 0.2 0.938 Wohlleben et al. [70]: Ti < 0.1 ppm
NM-110 ZnO 27.4 0.0 3.00 Wohlleben et al. [70]: Only soluble in acidic environments
NM-200 Amorphous SiO2 11.9 0.0 11.6 OECD [71]: 2.4 ± 0.03 mmol/l (corresponding to 67 mg/L)
NM-203 Amorphous SiO2 132 92.6 21.2 Wohlleben et al. [70]: Si: 56 ppm
NM-211 CeO2 62.6 5.8 2.14 Wohlleben et al. [70]: CeO2: < 0.1 ppm
NM-212 CeO2 132 0.3 0.776 Keller et al. [72]: 0.002 wt.%
NM-400 MWCNT 14.8 0.0 383 Insoluble, supernatant fully transparent
a For technical reasons (see text for details), ZnO NM-111 and MWCNT NM-401 and NM-402 were exempt from the characterization. Additionally, the substances
that were applied undiluted in the BCOP assay were exempt from the characterization
b The recorded value exceeds the total dose. Possibly, the refractive index increment for TiO2 (dn/dc = 0.376 cm
3/g) does not apply for TiO2 NM-100, e.g. due to its
exclusively anatase crystal structure
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28 mg b 22 mg b 23 mg b 17 mg b 12 mg b 6 mg b 12 mg b 25 mg b 6 mg b 2.5 mg b 61 mg b 28 mg b 50 μL 50 μL 46 mg c 32 mg c 8 mg c
Viability of tissue #1
relative to NC
99 107 105 79 70 97 96 116 107 88 92 81 42 62 88 109 98
Viability of tissue #2
relative to NC
83 107 106 79 86 106 100 113 105 91 70 81 48 71 95 105 100
Mean relative tissue
viability (and ITV%)
91 (16) 107 (1) 106 (1) 79 (0) 78 (16) 102 (9) 98 (5) 114 (3) 106 (2) 90 (3) 81 (22 d) 81 (0) 45 (6) 66 (9) 92 (7) 107 (4) 99 (2)
The mean tissue viability of 2 tissues / test group is expressed relative to the corresponding negative control (NC) value further indicating (in brackets) the relative inter-tissue variability (ITV%)
a Protocol variant 1: 30 min and 90 min exposure duration for liquids and solids, respectively; 12 min post-exposure immersion for both liquids and solids
b Corresponding to 50 μL bulk volume
c Corresponding to 2×50 μL bulk volume
d Since the inter-tissue variance of the two tissues was >20 %, the corresponding acceptance criterion was not met. However, since all other acceptance criteria were met and due to the unambiguous result recorded for the












Sigma Aldrich, Germany); Dulbecco’s phosphate buff-
ered saline (PBS) without Ca2+ or Mg2+ (also purchased
from Biochrom, Germany); MTT (also purchased from
Sigma Aldrich, Germany), and 1.0 mg/mL isopropanol.
Highly de-ionized water was used as negative control
(NC) and methyl acetate (purity >98 %, Chemical Abstracts
Service (CAS) No. 79–20–9, Merck KGaA, Germany) as
positive control (PC).
Pre-tests to determine direct MTT reduction For all
test materials, pre-tests as described in the OECD TG
492 were performed that precluded the test materials’
ability to directly reduce MTT.
Main tests In the main tests, two tissues were treated
with either the test materials, the NC or the PC. On the
day of arrival in the laboratory, the EpiOcular™ tissues
were transferred to sterile 6-well plates with 1 mL
DMEM and pre-conditioned at standard culture condi-
tions (37 °C, 5 % CO2, 90–95 % humidity) in the incubator
for 16–24 h. After pre-incubation, the tissues were pre-
treated with 20 μL PBS and further incubated at standard
culture conditions for 30 min. Using a sharp spoon or pip-
ette, the dry-powder or liquid test items, respectively, were
applied to cover the entire tissue surface (cf. 2.2.1). Con-
trol tissues were concurrently exposed to 50 μL highly de-
ionized water (NC) or methyl acetate (PC). After test ma-
terial application, the tissues were placed into the incuba-
tor for the following exposure periods: 90 min (solids;
variant 1), 6 h (solids; variant 2), or 30 min (liquids).
To remove the test materials, the tissues were washed
with sterile PBS and immediately immersed into 12-well
plates, pre-filled with 5 mL pre-warmed medium per
well to remove test material residuals. After 12 min
(solids, variant 1; and liquids) or 25 min (solids; variant 2),
each tissue was dried on absorbent paper and transferred
to fresh 6-well plates filled with 1 mL pre-warmed me-
dium per well (post-exposure immersion). Subsequently,
the tissues were incubated at standard culture conditions
(post-exposure incubation) for 18 h (solids; variants 1 and
2) or 2 h (liquids). During the post-exposure immersion
and incubation periods, weak cytotoxic effects might re-
verse, and more pronounced effects might increase.
Upon completion of the respective post-exposure periods,
the assay medium was replaced by 0.3 mL MTT solution.
After incubating the tissues for 3 h, the tissues were washed
with PBS to terminate the MTT incubation. The produced
formazan was extracted by incubating the tissues in isopro-
panol at room temperature overnight or on a plate shaker
for at least 2 h. The optical density of the formazan extracts
was determined spectrophotometrically at a wavelength of
570 nm (OD570). For each microtitre plate, blank values
were established from 4 wells filled with isopropanol.
Calculation of mean relative tissue viability Tissue
OD570 values were calculated by subtracting the mean
blank value of the respective microtitre plate from the
measured tissue OD570 value, and mean OD570 values
were calculated for the two tissues of each treatment
group. The quotient of the mean OD570 values of the
test material-treated tissues and those of the NC (i.e. the
mean relative tissue viability) was determined to evalu-
ate whether or not a test material is an irritant:
 Mean relative tissue viabilities ≤60 % indicated
‘irritancy to the eye’;
Table 4 Mean tissue viability of 15 OECD representative nanomaterials determined in the EpiOcularTM eye irritation test (protocol





















No. of test run 1st test run b 2nd test run b 3rd test run b 1st test run b 2nd test run
Volume or mass
applied
28 mg d 22 mg d 23 mg d 17 mg d 17 mg d 17 mg d 12 mg d 6 mg d 12 mg d 12 mg d
Viability of tissue
#1 relative to NC
108 92 96 30 41 102 89 98 74 63
Viability of tissue
#2 relative to NC
107 97 115 61 80 29 107 121 115 73
Mean relative tissue
viability (and ITV%)
108 (1) 95 (5) 106 (20 f) 45 (31) 60 (40) 66 (73) 98 (17) 109 (23 f) 94 (40) 68 (10)
The mean tissue viability of 2 tissues / test group is expressed relative to the corresponding negative control (NC) value further indicating (in brackets) the relative
inter-tissue variability (ITV%)
a Protocol variant 2 (performed only with solid test substances): 6 h exposure duration for solids; 25 min post-exposure immersion for solids
b Repeat of test run due to high variability >20 % (in the case of TiO2 NM-103: Cessation of testing after 3
rd inconclusive test run)
c Repeat of test run due to high optical density value (>130 % relative to the NC) of one of the measurements
d Corresponding to 50 μL bulk volume
e Corresponding to 2x50 μL bulk volume
f Even though the ITV% values laid close to the threshold value of 20 %, these test runs were not repeated, since the individual measurements clearly indicated
lack of toxicity
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 Mean relative tissue viabilities >60 % indicated
‘no irritancy to the eye’.
Acceptance criteria In case one of the following ac-
ceptance criteria (AC) as described in the OECD TG
492 was not met, repetition of the EpiOcular™-EIT was
considered.
 AC for the NC: The OD570 of the NC reflects the
laboratory-specific tissue viability under the specific
conditions of the assay. It was considered acceptable
if the mean OD570 of the NC was ≥0.8 and ≤2.5 and
the historical in-house mean at the respective time
of testing was met (variant 1: OD570 of NC for
liquids / solids: 1.490 ± 0.106 / 1.361 ± 0.138;
variant 2: OD570 of NC for solids: 1.650 ± 0.159).
 AC for the PC: In-house, the PC methyl acetate
usually elicits relative tissue viabilities of approx.
25 % (historical in-house means at the time of
testing in accordance with variant 1: OD570 of PC
for liquids/solids: 0.388 ± 0.098/0.318 ± 0.119;
variant 2: OD570 of PC for solids: 0.396 ± 0.098).
In addition to these
historical means, all relative tissue viability values
<50 % were considered acceptable.
 AC for tissue variability: The relative inter-tissue
variability (ITV%) between the two tissues of a
treatment group was considered acceptable if
it was ≤20 %.
BCOP assay
The BCOP assay was conducted according to OECD TG
437 [3].
Reagents and technical equipment, positive and
negative controls The following technical equipment
was applied: Corneal holders (LAB Research, Hungary,
or BASF SE, Germany), opacitometer (BASF-OP2.0,
BASF SE, Germany), spectrophotometer (Sunrise™ Ab-
sorbance Reader, Tecan Group Ltd. Switzerland, meas-
urement using filter wavelength of 490 nm without
reference filter). The following reagents were used (all
supplied by Biochrom AG, Germany, unless otherwise
noted): Hanks’ Balanced Salt Solution (HBSS) containing
1 % (v/v) Penicillin/Streptomycin (10 000 IU/10 000 μg/
mL); Eagle’s Minimum Essential Medium (MEM) with-
out phenol red containing fetal calf serum and 1 % (v/v)
Penicillin/Streptomycin; Eagle’s MEM with phenol red,
sodium fluorescein (Merck KGaA, Germany) diluted in
PBS.
Table 5 Mean tissue viability of aSiO2-susp, quartz dust DQ12, talc, and three organic pigments determined in the EpiOcular™ eye
irritation test (protocol variant 2 for solid test substances a)









No. of test run 1st test run 2nd test run b
Volume or mass applied 50 μL 50 μL 15 mg c 12 mg c 9 mg c 8 mg c 16 mg c
Viability of tissue #1 relative to NC 67 89 73 98 87 97 93
Viability of tissue #2 relative to NC 90 107 82 98 95 79.6 103
Mean relative tissue viability (and ITV%) 78 (23) 98 (18) 77 (10) 98 (0) 91 (8) 88 (18) 98 (10)
The mean tissue viability of 2 tissues / test group is expressed relative to the corresponding negative control (NC) value further indicating (in brackets) the relative
inter-tissue variability (ITV%)
a Protocol variant 2 for solid test substances: 6 h exposure duration for solids; 25 min post-exposure immersion for solids
b Repeat of test run due to high variability >20 %
c Corresponding to 50 μL bulk volume
Table 4 Mean tissue viability of 15 OECD representative nanomaterials determined in the EpiOcularTM eye irritation test (protocol









































25 mg d 25 mg d 6 mg d 6 mg d 2.5 mg d 2.5 mg d 61 mg d 61 mg d 28 mg d 46 mg e 32 mg e
Viability of tissue
#1 relative to NC
9 87 127 125 120 81 128 113 113 115 124
Viability of tissue
#2 relative to NC
131 94 134 95 137 111 131 105 97 106 117
Mean relative tissue
viability (and ITV%)
114 (34) 91 (7) 131 (7) 110 (30) 128 (17) 96 (30) 129 (3) 109 (8) 105 (16) 111 (9) 120 (7)
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Highly de-ionized water was used as NC. For the ma-
terials that were supplied as dry-powder test items, imid-
azole (CAS No. 288–32–4; Sigma Aldrich, Germany)
20 % (w/v) dissolved in highly de-ionized water was used
as PC. For Ag NM-300 K, its dispersant, Ag NM-300 K
DIS, and aSiO2-susp 1 % (w/v) sodium hydroxide (Sigma
Aldrich, Germany) diluted with highly de-ionized water
was used as PC.
Mounting of corneas and measurement of initial cor-
neal opacity Bovine corneas were mounted in corneal
holders. Both the anterior and posterior chambers of
these holders were filled to excess with pre-warmed Ea-
gle’s MEM (without phenol red). After equilibration in a
vertical position at 32 °C for at least 1 h, the medium in
both chambers was replaced with fresh pre-warmed
medium and the initial corneal opacity was measured.
Test material application, incubation and removal
Generally, each treatment group (NC, PC, or test material)
consisted of 3 corneas. Before application of the test mate-
rials, the medium in the anterior chamber was removed.
 For the NC, the anterior chambers were filled
with 750 μL highly de-ionized water and, for the PC,
with 750 μL of the 20 % (w/v) imidazole solution.
 For all TiO2, CeO2 and SiO2 NMs as well as ZnO
NM-110, 750 μL of the 20 % (w/v) test material
preparation was applied directly to the epithelial
surface of the cornea (i.e. using the ‘open chamber
method’).
 For Ag NM-300 K and Ag NM-300 K DIS, and
aSiO2-susp, 750 μL of the undiluted test material
dispersions were applied.
 For ZnO NM-111 and MWCNT NM-401
homogenous 20 % suspensions of the test material
in water could not be prepared. Therefore 33 mg
and 48 mg of undiluted dry-powder ZnO NM-111
and MWCNT NM-401, respectively, were applied
with a sharp spoon, covering the entire corneas
surface with these amounts.
 The volumes of MWCNT NM-400 and NM-402
were too high to allow preparation of a w/v
suspension. Therefore, 20 % (w/w) dry suspensions
were prepared mixing 750 mg MWCNT NM-400 or
NM-402 in highly de-ionized water shortly before
application by stirring with a spatula.
 Quartz dust DQ12, talc and the three organic
pigments Pigment Red 57:1, Pigment Yellow 95,
and Pigment Black 32 were applied undiluted
(120, 80, 48, 45, and 40 mg, respectively).
For all NMs that were delivered as dry-powder test
items and aSiO2-susp, the corneas were incubated in a
horizontal position at 32 °C for 4 h as prescribed for non-
surfactant solids in the OECD TG. Ag NM-300 K, and
Ag NM-300 K DIS were tested with a 10 min application
and 2-h post incubation protocol as prescribed for liquids.
Upon completion of the incubation period, the NC,
PC and test materials were removed from the anterior
chamber with a syringe, and the respective epithelia
were washed at least 3 times with Eagle’s MEM (contain-
ing phenol red) and once with Eagle’s MEM (without
phenol red). Both chambers were then refilled with fresh
Eagle’s MEM (without phenol red). In the second test
runs assessing Ag NM-300 K and Ag NM-300 K DIS,
the glasses of the cornea holders were removed for easier
test material removal. As assessed by IVIS and histopatho-
logical evaluation, this open chamber washing procedure
was shown not to injure corneal tissue (data not shown).
Measurement of final corneal opacity and permeability
and calculation of in vitro irritancy score The final cor-
neal opacity was measured, and the opacity change per
cornea was calculated by subtracting the initial from the
final opacity value. Subsequently, the mean opacity change
of the NC was subtracted thereby providing the corrected
opacity change. Test results were provided as means of all
corrected opacity changes per treatment group.
To determine corneal permeability, the medium in the
anterior chamber was replaced by 1 mL sodium fluores-
cein solution (5 mg/mL for solid test items; 4 mg/mL for
liquid test items) and incubated in a horizontal position
for 90 min at 32 °C. The amount of sodium fluorescein
that permeated through the corneas was measured spec-
trophotometrically. Three aliquots per cornea were
transferred to a 96-well microtitre plate and the optical
density value (OD490) was determined subtracting the
mean blank OD490 (blank = Eagle’s MEM without phenol
red) from the OD490 of each cornea. Corrected OD490
values were calculated by subtracting the mean OD490
values of the corresponding NC. Final test results were
calculated as means of all corrected OD490 values per
treatment group.
The In Vitro Irritancy Score (IVIS) was calculated per
treated cornea and finally the mean IVIS per treatment
group ± standard deviation (SD) was determined: IVIS =
mean opacity value + (15 x mean permeability value). An
IVIS >55 indicates a risk of serious damage to the eyes.
Acceptance criteria In case one of the following ACs
laid down in OECD TG 437 was not met, repetition of
the BCOP assay was considered.
 AC for the NC: The NC responses should be lower
than the established upper limits for background
opacity and permeability values for the respective
NC.
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 AC for the PC: The IVIS calculated for the PC
should not lie outside the twofold range of the SDs
of the historical mean (i.e. 88.0–147.1 for imidazole
and 101.6–204.0 for sodium hydroxide).
 AC for the treatment groups: At least 2 of the 3
corneas per treatment group should provide
predictions that coincide with the mean of all 3
corneas, and none of the corneas should provide a
discordant prediction of 10 IVIS units above or
below the cut-off threshold of 55.
Histopathological evaluation For histopathological
evaluation by light microscopy, the corneas were fixed
in 10 % neutral buffered formalin for at least 24 h and
trimmed along the whole diameter (2 stripes of 3–4 mm
width). They were histotechnically processed with a
standard method for light microscopy and stained with
Hematoxylin and Eosin (Merck KGaA, Germany). Histo-
pathological findings were assessed in the epithelium
based on the depth of injury by using a standard semi-
quantitative grading system (from 1 to 5) that is related
to the extent of affected cell layers beginning from the
corneal surface (squamous cell layer) down to the basal
cell layer. This depth of the injury has been proposed as
a predictor of the severity and reversibility of effects
[41–43] and has been taken up in an OECD guidance
document related to the BCOP assay [44]. In the stroma,
tissue swelling and keratocyte changes were evaluated.
These findings were summarized in a so-called Histo-
pathological Score of Irritation (HSI) assigned for each
cornea ranging from 0 = no irritation to IV = severe irri-
tation (cf. Kolle et al. [45] for further details). HSI IV
was assessed as ‘severe irritation’; HSI I, II and III were
overall assessed as ‘non-severe irritation’; HSI 0 was
regarded as no irritation.
Results
EpiOcular™-EIT
Fulfilment of the acceptance criteria
The ACs for the NC and the PC were always met in the
EpiOcular™-EIT performed in accordance with either the
protocol variants 1 and 2 (Additional file 1: Table SI-1). If
ACs for tissue variability were not met in specific test
runs, their repetition was considered (cf. Supplementary
Information for further details).
Test results, variant 1
After washing, test material residues were observed on
the EpiOcular™ tissues treated with the TiO2 or CeO2
NMs or MWCNT NM-401 or NM-402. However, since
none of the test materials was able to reduce MTT dir-
ectly, it was concluded that these residues do not to
interfere with the MTT assay.
For all dry-powder NMs, mean tissue viabilities above
60 % relative to the NC were calculated (Fig. 1 and
Table 3; cf. Additional file 1: Table SI-1 for the corre-
sponding NC and PC values). Hence, none of the dry-
powder NMs revealed eye irritation potential in the
EpiOcular™-EIT under the chosen test conditions (i.e. in-
dicating likelihood of ‘neither Category 1 nor 2’).
Eye irritating potential was only recorded for Ag NM-
300 K (individual relative tissue viabilities: 42 and 48 %;
mean relative tissue viability: 45 %; i.e. all values ranged
below the cut-off value of 60 % indicating likelihood of
‘either Category 1 or 2’). For the Ag dispersant Ag NM-
300 K DIS, a mean relative tissue viability of 66 % and
individual relative tissue viabilities of 62 and 71 % were
recorded, i.e. all values ranged above the cut-off value of
60 %, thereby indicating likelihood of ‘Non-category’.
Nevertheless, the mean relative tissue viability value re-
corded for Ag NM-300 K DIS was the second lowest
value determined for any of the 17 OECD representative
NMs and was just 1 % above the borderline range de-
scribed for the EpiOcular™-EIT in OECD TG 492. Since
the dispersed silver Ag NM-300 K elicited more pro-
nounced effects than its dispersant alone, the effects in-
duced by Ag NM-300 K in the EpiOcular™-EIT were
assessed as being – at least partially – elicited by the sil-
ver particles (Table 3).
Test results, variant 2
After the 1st test run conducted in accordance with
the EpiOcular™-EIT variant 2, mean relative tissue via-
bilities >60 % (indicating likelihood of ‘neither Category 1
nor 2’) with concordant satisfactory ITV% were deter-
mined for TiO2 NM-100, NM-101, NM-102, NM-104,
NM-105, CeO2 NM-212, and MWCNT NM-400 and
NM-401 (Fig. 1, Table 4 and Additional file 1: Table SI-2).
Also for aSiO2-susp, quartz dust 12, the three organic
pigments and talc the mean relative tissue viabilities con-
sistently exceeded 60 % (Table 5).
TiO2 NM-103 was submitted to altogether three test
runs. In the first two test runs, mean relative tissue via-
bilities of 45 and 60 % were recorded, however the
ITV% exceeded 20 % (cf. 3.1.1). Therefore TiO2 NM-103
was submitted to a 3rd test run. Here, slightly higher
relative tissue viability was recorded (66 %), but again
the ITV% exceeded 20 %. Therefore, the assessment of
TiO2 NM-103 was terminated and its outcome was eval-
uated as inconclusive (Fig. 1 and Table 4).
Due to failure to meet the AC for tissue variability or
high optical density values recorded in single measure-
ments of the 1st test run (cf. 3.1.1), two test runs each
were conducted to evaluate the eye irritating potential of
the other test materials: For the uncoated ZnO NM-
110, the final mean relative tissue variability value
(68 %) ranged just above the threshold value, whereas it
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attained 91 % for the coated ZnO NM-111. For SiO2
NM-200 and NM-203 and CeO2 NM-211, all individual
and mean relative tissue variability values ranged above
90 % (apart from one individual value of 82 % recorded
for SiO2 NM-203). Therefore, all of these findings were
assessed as indicating likelihood of ‘neither Category 1
nor 2’ even though the ITV% exceeded 20 % in the 2nd
test runs of the SiO2 NMs (Table 4).
BCOP assay
Fulfilment of the acceptance criteria
The AC for the NC was always met. Due to high opacity
scores, one PC did not meet the AC for the PC
(Additional file 1: Table SI-2). However, since all other
ACs were met and the test material results were unam-
biguous, the study was assessed as being valid. In case
the AC for the treatment groups was not met, repeti-
tion of the test run was considered (cf. Supplementary
Information for further details).
NM agglomeration
As determined by AUC and / or LD as relevant (cf. test mate-
rials and particle characterisation), most dry-powder NMs
suspended in water (i.e. as prepared for the BCOP assay) are
predominantly present as agglomerates around 1 μm diam-
eter. For MWCNT NM-400, agglomerate sizes even
exceeded 10 μm. Dispersed fractions of the total dose with
diameters up to 1 μm that exceeded 50 % of the total dose
(i.e. indicating higher dispersibility) were recorded for TiO2
NM-100, NM-101, and NM-104, SiO2 NM-203 and CeO2
NM-212. Only SiO2 NM-203 prevailed in small agglomerates
below 100 nm. Lower than 50 % of the total dose, but still
noteworthy fractions of small agglomerates below 100 nm
were further recorded for CeO2 NM-211 and TiO2 NM-100.
Test results, dry-powder test items
None of the OECD representative TiO2, SiO2, or
CeO2 NMs or MWCNTs induced serious eye damage
in the BCOP as assessed by the respective IVIS that
were far below the cut-off value of 55 (Fig. 2 and Table 6;
cf. Additional file 1: Table SI-2 for the corresponding NC
and PC values). Likewise, the coated ZnO NM-111 did
not induce serious eye damage in the BCOP (IVIS 0.01 ±
0.03). For the uncoated ZnO NM-110, a borderline result
of 49.5 ± 10.7 was obtained in the 1st test run (individual
cornea IVISs 48.5, 60.7, 39.4). Therefore, a 2nd test run was
performed indicating no serious eye damage (mean IVIS
16.1 ± 4.7; individual cornea IVISs 15.3, 21.1, and 11.9).
Fig. 1 Mean relative tissue viability of two EpiOcular™ tissues plus inter-tissue difference obtained in the EpiOcular™-EIT. Blue bars represent results
obtained applying the protocol for solids ‘variant 1’ (90 min exposure; 12 min post-exposure), green bars - protocol for solids ‘variant 2’ (6 h
exposure; 25 min post-exposure) and red bars - protocol for liquids (30 min exposure; 12 min post-exposure)
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Likewise, quartz dust DQ 12, the three organic pig-
ments and talc did not induce serious eye damage in
the BCOP, with all IVIS being 0 (Table 7).
Generally, no histopathological findings were observed
for the corneas treated with the dry-powder NMs. Min-
imal findings (mostly minimal multifocal or diffuse des-
quamation) were only observed for TiO2 NM-101, ZnO
NM-110, CeO2 NM-211 and NM-212, and for these
test materials an HSI of I (minimal) was assigned
(Table 8). Of note, for these four NMs, IVIS >15 were
calculated, whereas all dry-powder NMs without histo-
pathological findings had IVIS ≤15. Figure 3 presents the
histopathological image of a bovine cornea treated with
the negative control deionized water, and Fig. 4 the one
of a cornea exposed to CeO2 NM-211. For quartz dust
DQ12, one cornea remained without findings, whereas
minimal findings (multifocal desquamation) were re-
corded for two corneas (Table 8).
Test results, liquid test items
For Ag NM-300 K, varying amounts of the test material
remained on the cornea after the washing procedure of
the 1st test run causing dark-brown patches on the cor-
nea surface. Histological evaluation of these corneas in-
dicated mild (one cornea) or severe (two corneas) eye
irritation with an overall HSI of IV (Table 8 and Figs. 5
and 6). Due to the high variability between the individual
corneas of the 1st test run (individual cornea IVISs of
117.0, 212.0, and 49.1), a 2nd test run was performed
using the open chamber washing procedure to remove
residual test material from the cornea surfaces. The
mean IVIS of the second run was 54.7 ± 6.3 (with in-
dividual cornea IVISs of 62.0, 50.8 and 51.3). Even
though no residues were observed in the 2nd test run,
histopathological evaluation revealed that the corneal
epithelium was completely detached and missing.
Since such a finding was not observed in the 1st test
run, it was attributed to the intensified washing pro-
cedure and no HSI was assigned since it was possible
not differentiate whether the epithelium was missing
as a test material-related effect and/or due to a puta-
tive washing artefact. Concordantly, the permeability
measurements produced low values in the 1st test
run, but very high values in the 2nd test run (0.14 ±
0.08 versus 3.46 ± 0.46; Table 6). Based upon these
observations, the BCOP assay, as performed in the
present study, does not appear suitable to assess the
eye damaging potential of Ag NM-300 K.
Also for the Ag dispersant Ag NM-300 K DIS,
high variability between the individual corneas used
Fig. 2 Mean BCOP assay IVIS (opacity + 15 x permeability) plus standard deviation. Abbreviations: IVIS: in vitro irritation score
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in the 1st test run was recorded (mean IVIS: 45.0 ±
16.7 with individual cornea IVISs of 60.1, 47.9, and
27.1), and a 2nd test run was performed using the
open chamber washing procedure (albeit only with 2
corneas since the available test material was not suffi-
cient to treat a third cornea; with individual IVIS
scores of 65.7 and 81.7, respectively). Accordingly, of
the total of five corneas tested, two produced IVIS
below the cut-off for serious eye damage and three
corneas produced values above this value. The overall
mean IVIS for both test runs was calculated to be
56.5. Hence, it ranged just above the cut-off value of
55 indicating a potential for serious or irreversible
eye damage, however very close to the cut-off and
with a rather high SD of 20.5. Due to this high inter-
cornea variability, the borderline positive BCOP result
for Ag NM-300 K DIS was assessed as inconclusive.
Histological evaluation (Table 8) revealed changes in-
dicating mild (1st test run; HSI: II; Fig. 7) or severe
eye irritation (2nd test run; HSI: IV; Fig. 8).
For aSiO2-susp, the IVIS was determined to be 15.4
(i.e. far below the cut-off value of 55; Table 7), and mild
findings (diffuse cell loss; HSI II) were observed in the
histopathological evaluation (Table 8).
Two-tier EpiOcular™ - BCOP eye irritation testing strategy
According to the results of the EpiOcular™-EIT, all dry-
powder test items and aSiO2-susp would be classified as
‘neither Category 1 nor 2’ substances, i.e. as having no eye
irritating potential. By contrast, Ag NM-300 K would be
classified as ‘Category 1 or 2’, i.e. as having the potential to
either induce serious, irreversible or reversible eye damage.
Further according to the results of the EpiOcular™-EIT, the
Ag dispersant Ag NM-300 K DIS would be classified as
‘Non-category’ substance even though its relative tissue via-
bility score (66 %) lay close to the cut-off value of 60 %.
In agreement with the results obtained for the dry-
powder test items and aSiO2-susp in the EpiOcular™-
EIT, also in the BCOP assay, the metal and metalloid
oxide NMs (ZnO, TiO2, CeO2, SiO2) and the
MWCNTs were assessed as not inducing severe eye
damage, i.e. as being ‘Not category 1’.
Ag NM-300 K was assessed as ‘Category 1 or 2’ in the
EpiOcular™-EIT. Accordingly, in a 2-tiered bottom-up test-
ing strategy the results from the BCOP assay should be used
to distinguish ‘Category 1’ from ‘Category 2’ substances [25].
The results of the BCOP assay for Ag NM-300 K, however,
did not allow a definite evaluation. In the BCOP assay, the
borderline positive outcome for the silver dispersant Ag
NM-300 K DIS, ranging just above the cut-off value indicat-
ing severe irritation, remains inconclusive due to high inter-
cornea variability. Taking into account that Ag NM-300 K
DIS also elicited an effect (albeit negative) close to the cut-
off value in the EpiOcular™-EIT, the eye damaging potential
of this liquid surfactant could not be ruled out, but also
could not be assessed with certainty in the present study.
Interestingly, whereas none of the silicon dioxide test ma-
terials revealed eye irritating potential in either the EpiOcu-
lar™-EIT or the BCOP assay, during histopathological
evaluation only the two dry powder test items amorphous
precipitated SiO2 NM-200 and amorphous pyrogenic SiO2
NM-203 remained without findings, whereas a HSI of 0-I
was recorded for the dry powder crystalline quartz dust
DQ12 and a HSI of II for the amorphous aSiO2-susp that
was provided as 40 % suspension.
Discussion
Relevance of study results for hazard assessment
A broad panel of inorganic NMs covering one metal NM
(Ag), different metal oxides (anatase, rutile and anatase-
rutile TiO2, coated and uncoated ZnO, uncoated CeO2),
three amorphous SiO2 (two supplied as powders and one
as suspension), and three MWCNTs, three organic pig-
ments, as well as non-nanosized quartz dust and talc were
submitted to in vitro eye irritation studies. Selecting test
materials from the set of OECD representative NMs
aimed at facilitating comparability of the test results to
studies performed by other research groups. Taking into
Table 6 Mean opacity and permeability values and corresponding in vitro irritation score (IVIS) of 16 OECD representative
nanomaterials (and the Ag NM dispersant) determined in the BCOP assay
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4.2 ± 7.2 24.7 ± 4.8 10.7 ± 6.1 23.8 ± 6.8 10.7 ± 4.3 2.2 ± 2.8 46.6 ± 9.1 15.0 ± 3.0 1.1 ± 1.1 9.7 ± 3.4
Mean permeability
value ± SD
−0.01 ± 0.00 0.22 ± 0.31 −0.12 ± 0.01 0.14 ± 0.18 0.04 ± 0.04 0.00 ± 0.00 0.20 ± 0.10 0.08 ± 0.12 0.01 ± 0.03 0.02 ± 0.05
IVIS ± SD 4.1 ± 7.1 28.0 ± 4.2 10.6 ± 6.2 25.9 ± 5.7 11.2 ± 4.0 2.2 ± 2.8 49.5 ± 10.7 16.1 ± 4.7 1.2 ± 0.7 10.0 ± 4.0
NM-300 K and Ag NM-300 K DIS were tested using the BCOP treatment protocol for liquids (10 min test substance exposure, 2 h post-exposure incubation) while
all others were tested according to the treatment protocol for solids (4 h test substance exposure without further post-incubation)
Abbreviations: IVIS In vitro irritation score, NC negative control, PC positive control, SD standard deviation
a Only two corneas were treated, since the available test substance was not sufficient to treat a third cornea
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account that none of the dry-powder test items (i.e. all test
materials, except for Ag NM-300 K, Ag NM-300 K DIS,
and aSiO2-susp) elicited eye irritation in either the EpiO-
cular™-EIT (using 2 protocol variants) or the BCOP assay
including histopathological evaluation, the following para-
graphs discuss the relevance of this outcome for human
eye irritation assessment.
The EpiOcular™-EIT has been reported to have an over-
all low false negative rate of 4 % [4]. By contrast, a high
false negative rate specifically for solids has been recorded
for the BCOP assay (that contributes to the overall false
negative rate of 14 % in determining ‘Category 1’ sub-
stances [3]). However, insoluble (solid) test items are gen-
erally difficult to apply in many in vitro test systems, and
they may also lead to variable exposure conditions in vivo,
for instance by causing mechanical corneal irritation in
addition to toxicological effects [3, 46].
The results from the BCOP assay were only evaluated to
determine whether test materials might cause severe or ir-
reversible eye damage as determined if the IVIS exceeds
the threshold value of 55. In accordance with the revised
OECD TG 437 [3], additionally, an IVIS ≤3 indicates that
the test material does not cause eye irritation or corrosion
and may be assessed as ‘Non-category’. In the present
study, IVIS ≤3 were obtained for TiO2 NM-105 and
coated ZnO NM-111, but not for the corresponding non-
coated ZnO NM-110 for which a borderline IVIS of 49.5
was determined in the 1st test run and an IVIS of 16.1 in
the 2nd test run. This may indicate that material coating
or surface functionalization may mitigate unwanted ef-
fects. In a rat short-term inhalation study, the histopatho-
logical effects caused by coated ZnO NM-111 in the rat
lung were less severe or had a lower incidence than those
elicited by micron-scale uncoated ZnO [7] and in rat
precision-cut lung slices ZnO NM-110 elicited more pro-
nounced cytotoxicity than ZnO NM-111 [38]. Addition-
ally, IVIS ≤3 were recorded for quartz dust DQ12, the
three organic pigments, and talc.
Ag NM-300 K was supplied in suspension and the cor-
responding dispersant (Ag NM-300 K DIS) without Ag
was also evaluated. In the EpiOcular™-EIT, Ag NM-
300 K was assessed as ‘Category 1 or 2’. When applying
this test material in the BCOP assay, dark-brown patches
remained on the surface of the treated corneas (unless
the washing procedure was intensified, which however
resulted in detachment of the corneal epithelium). In
vivo, discolouration of the cornea that is not reversible
within 21 days would result in the test material’s classifi-
cation as ‘eye irritant’. However, for Ag NM-300 K, in
vivo data are unavailable. Therefore, the in vivo rele-
vance of the outcome of the BCOP assay remains un-
clear. Recently, Plodikova et al. reported how different
modifications of the rinsing procedure within the
BCOP assay may enhance the removal efficiency of highly
viscous and coloured samples. Depending on the selected
rinsing procedure, the calculated IVIS values were signifi-
cantly altered, mainly due to altered opacity scores,
whereas the permeability values mostly remained un-
affected [47].
The outcomes of both the EpiOcular™-EIT and BCOP
assay were negative for the second NM that was sup-
plied in suspension, i.e. aSiO2-susp, and a HSI of II was
recorded upon histopathological evaluation of the cor-
neas treated with aSiO2-susp. Accordingly, for all three
Table 6 Mean opacity and permeability values and corresponding in vitro irritation score (IVIS) of 16 OECD representative
nanomaterials (and the Ag NM dispersant) determined in the BCOP assay (Continued)
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11.8 ± 3.7 18.0 ± 9.9 17.2 ± 5.4 123.9 ± 80.6 2.8 ± 0.6 43.9 ± 16.3 66.6 ± 2.9 −4.7 ± 2.2 −5.4 ± 0.7 −3.8 ± 0.8
Mean permeability
value ± SD
0.03 ± 0.05 0.03 ± 0.04 −0.02 ± 0.01 0.14 ± 0.08 3.46 ± 0.46 0.08 ± 0.03 0.48 ± 0.56 −0.01 ± 0.00 0.01 ± 0.03 −0.01 ± 0.01
IVIS ± SD 12.2 ± 2.9 18.5 ± 10.5 16.9 ± 5.3 126.0 ± 81.8 54.7 ± 6.3 45.0 ± 16.7 73.7 ± 11.3 −4.8 ± 2.3 −5.3 ± 0.4 −3.9 ± 0.7
Table 7 Mean opacity and permeability values and corresponding in vitro irritation score (IVIS) of aSiO2-susp, quartz dust DQ12, talc,
and three organic pigments determined in the BCOP assay
Test material aSiO2-susp Quartz dust DQ12 Pigment Red 57:1 Pigment Yellow 95 Pigment Black 32 Talc
Volume or mass applied 750 μL 120 mg 48 mg 45 mg 40 mg 80 mg
Mean opacity value ± SD 14.9 ± 4.7 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Mean permeability value ± SD 0.04 ± 0.02 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
IVIS ± SD 15.4 ± 4.5 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
All substances were applied undiluted using the BCOP treatment protocol for solids (4 h test substance exposure without further post-incubation)
Abbreviations: IVIS In vitro irritation score, NC negative control, PC positive control, SD standard deviation
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liquid (suspended) test items, higher HSI of II-IV were
recorded than for the dry-powder test items (HSI of 0-I).
Comparison of in vitro and in vivo eye irritation
To elucidate the relevance of the outcomes of the BCOP
assay and the EpiOcularTM-EIT for hazard assessment,
in the following, they are compared to the outcomes of
in vitro or in vivo eye irritation studies investigating
other TiO2, ZnO, amorphous SiO2, CeO2, Ag, MWCNTs,
or organic pigments. For the organic pigments, the exist-
ing in vivo eye irritation studies had been performed with
the same sample in case of Pigment Black 32 or with
samples of comparable grades. Therefore, direct in vitro-
in vivo comparisons are possible for these test
materials. For the other test materials, studies asses-
sing non-nanosized counterparts were also taken into
consideration, such as the key studies recorded in the
corresponding REACH dossiers (www.echa.europa.eu/in
formation-on-chemicals; accessed 7 April 2016).
In this respect, it should further be noted that the
present data sets are not a subject for statistical ana-
lysis. Neither OECD TG 492 nor 437 require statis-
tical analysis. While Cooper statistics are beneficial to
analyze the predictive capacity of a new method, it
was not applied it since the majority of in vitro-in
vivo comparisons were only based upon assessments
of comparable materials of the same chemical com-
position. Further, no dose-/concentration response
Table 8 Histopathological evaluation of the bovine corneas incubated with 16 OECD representative nanomaterials or the Ag dispersant
Test material Test run HSI Histopathological findings
TiO2 NM-100 1 0 Multifocal brown pigment remnants on squamous surface
TiO2 NM-101 1 I Multifocal desquamation and brown granules on the epithelial surface
TiO2 NM-102 1 0 Brown granules on squamous surface
TiO2 NM-103 1 0 No findings
TiO2 NM-104 1 0 No findings
TiO2 NM-105 1 0 No findings
ZnO NM-110 1 I Multifocal desquamation
ZnO NM-110 2 I Diffuse desquamation
ZnO NM-111 1 0 No findings
SiO2 NM-200 1 0 No findings
SiO2 NM-203 1 0 No findings
CeO2 NM-211 1 I Multifocal vacuolation in the squamous and wing cell layers; multifocal
desquamation and brown granules on the epithelial surface
CeO2 NM-212 1 I Multifocal desquamation and brown granules on the epithelial surface
Ag NM-300 K 1 IV All corneas: diffuse cell loss in the squamous and wing layers; two corneas,
additionally: multifocal eosinophilic precipitate on the basal lamina; multifocal
cell lysis in the basal layer; pyknosis of the upper keratocytes of the stroma
Ag NM-300 K 2 n.e. Corneal epithelium completely detached and missing
Ag dispersant NM-300 K DIS 1 II Diffuse vacuolation / edema of the squamous and upper wing cell layers;
desquamation of the squamous cell layer
Ag dispersant NM-300 K DIS 2 IV Multifocal vacuolation of basal layer, epithelial detachment from basal lamina,
multifocal eosinophilic precipitate between basal layer and stroma
MWCNT NM-400 1 0 No findings
MWCNT NM-401 1 0 No findings
MWCNT NM-402 1 0 No findings
aSiO2-susp 1 II Diffuse cell loss
Quartz dust DQ12 1 0-I 1 cornea: no findings; 2 corneas: multifocal desquamation
Pigment Red 57:1 1 0 No findings
Pigment Yellow 95 1 0 No findings
Pigment Black 32 1 0 No findings
Talc 1 0 No findings
HSI histopathological score of irritation (HSI) of 0 = no findings, I =minimal, II =mild, III =moderate, IV = severe
n.e = evaluation not possible due to technical artefacts
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curves could be recorded so that statistical analyses
that are founded on such curves could also not be
performed.
To date, there are no provisions in EC regulation
1907/2006 (REACH [1]) referring specifically to NMs.
The legislative text deals with substances, as such, in
whatever size, shape or physical state. Since substances
at the nanoscale are substances in a specific form, they
are included in the general registration dossier [1, 48].
Accordingly, NMs for which a bulk counterpart exists
are registered together with this counterpart. The EU
Commission [49] advised that NMs should be classified
on a case-by-case basis giving due consideration to
relevant available data on, e.g., the bulk form and read-
across to other NMs.
Against this background, the eye irritancy categories
assigned to the test materials as an outcome of the
present study were compared to eye irritancy classifica-
tions from the REACH registration dossiers for titanium
dioxide, zinc oxide, silica (covering all crystalline and
amorphous SiO2), cerium dioxide, silver, and a specific
MWCNT. The industrial mineral talc is exempt from
REACH registration.
In all of these REACH dossiers, the key studies for eye
irritation were in vivo tests performed in accordance
with OECD TG 405. Mostly, rabbits were used, with the
Fig. 5 Bovine cornea treated with Ag NM-300 K (10x, HE stain); HSI:
IV. A Diffuse cell loss of squamous and wing cell layers;: Multifocal
karyolysis in the basal cell layer (↑). Abbreviations: HE: Hematoxylin
and Eosin; HSI: Histological score of irritation
Fig. 6 Bovine cornea treated with Ag NM-300 K (10x, HE stain); HSI:
IV. Diffuse cell loss of squamous and wing cell layers; Multifocal
karyolysis in the basal cell layer (↑) and Ag NM-300 K particle
residues (*). Abbreviations: HE: Hematoxylin and Eosin; HSI:
Histological score of irritation
Fig. 3 Bovine cornea treated with negative control deionized water
(10x, HE stain); HSI: 0. A Squamous cell layer; B wing cell layer; C
Basal cell layer; D Stroma. Abbreviations: HE: Hematoxylin and Eosin;
HSI: Histological score of irritation
Fig. 4 Bovine cornea treated with CeO2 NM-211 (10x, HE stain); HSI:
I. A Multifocal vacuolation in the squamous and upper wing cell
layers; multifocal desquamation and brown particle residues (*) on
epithelial surface. Abbreviations: HE: Hematoxylin and Eosin; HSI:
Histological score of irritation
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exception of the first key study for Ag (which corre-
sponds to Maneewattanapinyo et al. [21]), which was
performed using guinea pigs. For TiO2, SiO2, and Ag,
key studies for eye irritancy assessment were conducted
with NMs, the tested MWCNTs are NMs, as such, and
organic pigments fall under the EU recommendation for
the definition of NMs ([24] but are exempt from certain
national NM-specific legislation). In the REACH dossier
for ZnO, two supporting studies correspond to the
EpiOcular™-EIT and BCOP assessments for ZnO NM-
110 of the present study. In none of the mentioned
REACH dossiers, eye irritancy Categories 1 or 2 were
assigned (Table 1).
Hence, the eye irritancy assessments of the mentioned
REACH dossiers back up the lack of effects observed for
the NMs that were supplied as powder in the EpiOcu-
lar™– BCOP eye irritation testing strategy. Also for the
organic pigments, mild transient effects clearly below
the threshold for classification and labelling were re-
corded in the available in-house in vivo studies which is
consistent with the outcome of the BCOP assay and
EpiOcular™-EIT.
Similarly, in its Opinion on nanoform TiO2, the EU
Commission’s Scientific Committee on Consumer Safety
(SCCS; [50]) comes to the conclusion that the eye irrita-
tion potential of TiO2 NMs appears to be low. However,
the SCCS cautions that this assessment is predominantly
based upon two in vivo eye irritation studies assessing
15 % anatase / 85 % rutile TiO2 coated with trimethoxy-
n-octyl-silane. In its Opinion on nanoform ZnO, the
SCCS [51] assessed an uncoated ZnO NM (20 nm; dos-
age: 0.1 g of neat test material or 0.1 mL of a 25 % solu-
tion in olive oil) as being a ‘mild irritant’, also basing this
conclusion on an in vivo rabbit eye irritation study. An
extensive evaluation of the toxicological profile of nano-
sized and non-nanosized ZnO found the effects elicited
by either material to be very similar [52].
In the REACH dossier for silver, two key studies for
eye irritation were conducted with Ag NM suspensions
(one of which an aqueous solution, the other one not
further specified in the key study) and one key study
with an Ag NM powder that was applied directly into
the conjunctival sac of the rabbit eyes. Whereas no ocu-
lar effects were observed upon treatment with the Ag
NM powder, the Ag NM suspensions caused minimal
and fully reversible conjunctival redness in single ani-
mals only. All three key studies came to the conclusion
that the tested Ag NMs were not irritating. Based upon
the outcome of the 2-tier in vitro testing strategy applied
in the present study, the surfactant-dispersed Ag NM-
300 K preparation appears to elicit more pronounced
eye irritation than Ag NMs that are supplied as powders
or in aqueous suspension, and dark-brown patches
remained on the surface of the corneas treated with Ag
NM-300 K. In its Opinion on nanosilver, the EU Com-
mission’s Scientific Committee on Emerging and Newly
Identified Risks [53] highlighted a permanent bluish-grey
discolouration of the skin or eyes as being the predom-
inant adverse effects elicited by chronic human exposure
to silver, as was also reported by Chiou [22]. Addition-
ally, exposure to soluble silver compounds was reported
to possibly produce liver and kidney damage, irritation
of the eyes, skin, respiratory, and intestinal tract, and
changes in blood cells [53].
In regard to available in vitro studies addressing the
eye irritancy of NMs intended for non-medicinal uses,
Sanders et al. exposed human ARPE-19 retinal pigment
epithelial cells to 0.3-100 μg/ml of differently sized ana-
tase, rutile and anatase/rutile TiO2 NMs. After 24-h test
Fig. 7 Bovine cornea treated with Ag NM-300 K DIS (10x, HE stain);
HSI: II. A Diffuse edema / vacuolation of the squamous and upper
wing cell layers; B desquamation of the squamous cell layer.
Abbreviations: HE: Hematoxylin and Eosin; HSI: Histological score
of irritation
Fig. 8 Bovine cornea treated with Ag NM-300 K DIS (10x, HE stain);
HSI: IV. A Vacuolation of all epithelial cell layers, accentuated in the
basal cell layer B Abbreviations: HE: Hematoxylin and Eosin; HSI:
Histological score of irritation
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material exposure in the live/dead calcein-AM and pro-
pidium iodide assay with subsequent 4-h exposure con-
tinuation under UV radiation, the smaller TiO2 NMs
(primary particle size (PPS): 25 and 31 nm; Transmission
Electron Microscopy (TEM)) elicited the most pro-
nounced phototoxicity (LC50 < 5 μg/ml), whereas the lar-
gest TiO2 NMs (PPS: 142 nm and 214 nm; TEM) were
the least toxic [54]. In cultured eye-associated cells, Ag
NMs supplied as aqueous suspensions did not affect cell
viability: In human HCE-T corneal epithelial cells or eye-
associated murine RAW264.7 macrophages, 2-6 μM Ag
NMs/mL (PPS: 40 nm; 10 ppm Ag in the colloids) did
not significantly affect cell viability, as assessed by cell
counts and adenylate kinase release from damaged cells,
nor did they induce different interleukins [55]. Evidently,
the test systems and endpoint detection methods se-
lected in the present study differ from those applied in
the studies by Sanders et al. [54] and Santoro et al. [55]
thereby impeding comparability of the test results. In rat
precision-cut lung slices, Ag NM-300 K elicited pro-
nounced tissue destruction, at effective in vitro dosages
of up to 12 μg/cm2 cell culture surface area [38].
Mechanisms of nanomaterial eye irritation
Increasingly, it is being recognized that nanoscale par-
ticle size alone does not dictate toxicity, but that intrin-
sic and system-dependent (i.e. test system-, matrix- or
environment-dependent) material properties, such as
chemical composition, solubility, and dispersibility, are
more relevant determinants of NM toxicity [7, 8, 56, 57].
These material properties differ considerably for the 16
OECD representative NMs (cf. also Tables 1 and 2): The
metal NM Ag NM-300 K and the uncoated and coated
metal oxides ZnO NM-110 and NM-111, respectively,
are soluble in water or biological media. Due to their
chemical composition, these materials, upon dissolution,
may shed toxic ions. By comparison, TiO2 and CeO2
NMs are poorly soluble, and the amorphous SiO2 NM-
200 and NM-203 are partly soluble. For these metal
oxide and metalloid oxides, the toxic potential, e.g. upon
inhalation, is strongly affected by their respective bioper-
sistence. For the MWCNTs, just as other fibres, a high
aspect ratio combined with fibre rigidity and biopersis-
tence accounts for toxic potential [57]. Of note, accord-
ing to the ‘exclusion rules for eye irritation’ from the
German Federal Institute for Risk Assessment, substances
of very high molecular weight (>650 g/mol) and of very
poor solubility in water and lipids are non irritating to
the eye [58].
Taking into account their intrinsic and system-
dependent material properties, knowledge on the mech-
anisms of toxicity of NMs is increasingly becoming
available, albeit predominantly for the inhalation route
of exposure. For Ag and ZnO NMs, toxicity appears
mainly determined by the potential to shed toxic ions.
These materials frequently elicit pronounced cytotoxicity
in vitro, and in rats ZnO NMs have been observed to
cause necrosis of the olfactory epithelium, the primary
site of contact upon inhalation [7, 8]. TiO2 and CeO2
NMs may elicit the production of reactive oxygen spe-
cies and inflammatory reactions; amorphous SiO2 has
been observed to elicit membrane damage and lysis, and
MWCNTs may cause fibre-related toxic effects [8, 59].
Against this background, it remains to be determined
whether the mechanisms of toxicity (and underlying key
material properties) that are relevant for the inhalation
exposure route might also be determinants of effects
upon topical exposure to the eye. For eye irritation, four
different known modes-of-action have been described,
i.e. (I) cell membrane lysis (breakdown of membrane in-
tegrity as might be elicited by, e.g., surfactants; such as
the Ag NM-300 K dispersant), (II) saponification (break-
down of lipids by alkaline action), (III) coagulation (pre-
cipitation/denaturation of macromolecules), and (IV)
actions on cellular macromolecules [44].
To account for the underlying biological processes that
ultimately result in eye irritation classifications [60], it
has been requested to incorporate mechanistic informa-
tion into in vitro eye irritation testing strategies. For in-
stance, the reversibility of effects may be reflected by
corneal repair and recovery mechanisms (for reversibility
of effects), such as renewal of the superficial lining of
the corneal epithelium [33]. In an in vitro wound healing
array, in which human corneal fibroblasts or human cor-
neal epithelial cells were cultured to confluence with sub-
sequent production of a ‘wound’ and imaging of the
healing process and cell migration, ZnO NMs (PPS: 40-
100 nm; hydrodynamic diameter in DMEM-F12 supple-
mented with 10 % fetal calf serum (DLS): 162 nm) were
observed to impede both cell viability and wound healing
[61]. These effects occurred at 15.8 μg/mL in the epithelial
monolayers and at 45.2 μg/mL and above in the fibroblast
cultures. By contrast, up to 108 μg/mL amorphous SiO2,
and TiO2 (PPS: 55 nm, and 25 nm, respectively; hy-
drodynamic diameter: 172 nm, and 838 nm, respectively)
elicited no such effects on the corneal cells [61]. Monodis-
perse SiO2 NMs (spherical (TEM); 40 nm (DLS); no fur-
ther particle characterisation), however, applied in 1 mg/
mL aqueous suspensions, were found to penetrate across
isolated human corneal buttons [62].
As described in the OECD guidance document [44],
the BCOP assay conducted in accordance with OECD
TG 437 addresses the first three modes-of-action recog-
nized for eye irritation (i.e. cell membrane lysis, saponifi-
cation, and coagulation), and the fourth one (actions on
cellular macromolecules) might also be addressed if
histopathological information is available. In the present
study, histopathological evaluation of the corneas
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submitted to the BCOP assay was performed to corrob-
orate the outcome of this assay and potentially to con-
tribute to defining mechanisms of eye irritancy of the
tested NMs. In an earlier study investigating a broad
spectrum of non-nanosized materials in the BCOP assay,
histopathological assessment of the corneas corrected
the classification of some false negatives, but also in-
creased the overall number of false positives [26].
Since none of the dry-powder NMs elicited eye irrita-
tion in either the EpiOcular™-EIT or the BCOP assay in
the present study, and the corresponding histopatho-
logical evaluation of the treated corneas resulted in very
low HSI of 0 or I, the results of the current study do not
provide information on different modes of eye irritating
action for dry-powder NMs. Presumably, they are simply
not eye irritating.
The surfactant Ag NM-300 K DIS, either alone or as
dispersant in Ag NM-300 K most likely elicited the first
mode-of-action for eye irritation, i.e. cell membrane
lysis. Of note, the Ag NM-300 K DIS component Tween
20 is non-irritant both in vivo and in vitro [3]. It is cur-
rently unclear whether effects caused by Ag NM-300 K
in the EpiOcular™-EIT and BCOP assay are – at least
partially – attributable to the shedding of toxic ions.
Likewise, it is unclear if the discolouration of the cornea
would also be observable in vivo, and if so, if it would
persist throughout 21-days post-administration resulting
in classification of the material.
Applicability of the EpiOcular™ - BCOP eye irritation
testing strategy for the testing of nanomaterials
According to the results of the EpiOcular™-EIT, all dry-
powder test items and aSiO2-susp would be classified as
having no eye irritating potential. In agreement with this
outcome, all of these test materials were assessed as not
inducing severe eye damage, i.e. as being ‘Not category
1’ in the BCOP assay. Hence, for dry-powder NMs, the
results of the present study point to the overall low eye
irritating potential of these test materials.
Regarding the observations made for Ag NM-300 K
and its dispersant Ag NM-300 K DIS, both in the EpiO-
cular™-EIT and the BCOP assay, further research is ne-
cessary to determine if the silver nanoparticles may
cause eye irritating effects, either alone or in combin-
ation with the dispersants. The difficulties encountered
when testing Ag NM-300 K and Ag NM-300 K DIS in
the BCOP assay might not be specific to NMs, but
may be similar to the ones commonly occurring when
testing non-nanosized liquid and surfactant materials.
Since oftentimes it is exactly such specific prepara-
tions of NMs that end up being handled either in occupa-
tional or consumer-related contexts, hazard assessment of
the specific NM preparation is relevant for safety
measures.
The EpiOcular™ – BCOP eye irritation testing strategy,
as it was applied in the present study to assess a broad
spectrum of NMs, follows the recommendations of the
GHS [6] and the supplement to the updated OECD TG
405 on in vivo acute eye irritation and corrosion testing
[2]. This supplement proposes a sequential testing strat-
egy for eye irritation and corrosion that predominantly
makes use of in vitro or ex vivo assays restricting in vivo
testing to materials eliciting equivocal results in the
non-animal test tiers. General applicability of the 2-tier
testing strategy to distinguish ‘Category 1’ from ‘Cat-
egory 2’ eye irritancy of NMs cannot be assessed by the
outcome of the present study since only one material
(i.e. Ag NM-300 K) was assessed as ‘Category 1 or 2’ in
the EpiOcular™-EIT. As long as comprehensive data for
NM in vitro and in vivo eye irritation potential covering
the different relevant mechanisms of toxicity are unavail-
able, the applicability of the EpiOcular™ – BCOP eye ir-
ritation testing strategy to determine if a NM should be
classified as either ‘Category 1’, ‘Category 2’ or ‘non-Cat-
egory’ cannot be assessed with certainty. Nevertheless,
the consistently negative findings obtained for the dry-
powder NMs in both in vitro assays stand in accordance
with eye irritation classifications in corresponding
REACH registration dossiers.
A number of specificities have to be taken into ac-
count for in vitro testing of NMs, and these specificities
also point to aspects of the OECD TGs that might re-
quire modification for NM testing as cautioned by the
OECD WPMN [36]. For instance, the agglomerating
properties of NMs in suspensions have to be addressed
in the course of in vitro testing. The extent of NM ag-
glomeration may affect its diffusion and sedimentation
properties which in return may affect the proportion of
the applied dose that reaches the in vitro test system
within the given exposure duration [8, 37, 63, 64]. The
differences between in vitro and in vivo effective dosages
of identical test material preparations are expected to be
much less pronounced in the context of local toxicity
testing, than the differences recorded for inhalative or
systemic effects. For local toxicity testing, NMs are dir-
ectly topically applied to the 3D-test systems rather than
suspended in cell culture media as required for most cel-
lular assays. In the EpiOcular™-EIT, the test materials are
applied undiluted. This may be an advantage for NM
testing, since one may assume that the material prevails
on the test system as supplied and that diffusion and
sedimentation properties do not affect the effective in
vitro dosage.
By contrast to the solids protocol variant 1, performing
the EpiOcular™-EIT in according to protocol variant 2
resulted in overall high variability in tissue viability. For
one dry-powder test material (TiO2 NM-103) it was
even not possible to obtain acceptable inter-tissue
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variability within a total of 3 test runs. In fact, variant 2
of the EpiOcular™-EIT was performed after all dry-
powder NMs tested negative in variant 1 to investigate
whether the 90 min incubation period (as compared to
6 h in variant 2) and the 12 min post-exposure
immersion period (as compared to 25 min in variant 2)
might have been too short for effects to evolve. Thereby,
this part of the study served to follow up the solids’
protocol optimization for increased sensitivity described
by Kaluzhny et al. [65] and that has been taken up in the
OECD TG 492. Taking into account the considerably
higher variability observed in the EpiOcular™-EIT proto-
col variant 2 as compared to variant 1, it remains a mat-
ter for further investigation to address whether the
increased incubation or post-exposure immersion pe-
riods are possibly disadvantageous for the testing of
NMs. Generally, the updated (i.e. ‘variant 2’) test proto-
col of the EpiOcular™-EIT has been validated to provide
excellent sensitivity [4, 65].
In the BCOP assay, solid test materials are generally
applied diluted in highly deionized water. The lack of
protein addition to the suspension is known to promote
agglomeration [37, 66, 67], and, apart from SiO2 NM-
203 that prevailed in small agglomerates below 100 nm
diameter, all dry-powder NMs strongly agglomerated in
water. If the NMs agglomerate, sedimentation prevails
over diffusion, which increases the likelihood that a
higher proportion of the test materials will reach the in
vitro test system [63, 64]. In further addressing possible
adaptations of the BCOP assay protocol for NM testing,
it might be assessed whether neat testing might better
mimic the in vivo situation. (In the present study, ZnO
NM-111 and MWCNT NM-401 were applied as un-
diluted solids in the BCOP assay since homogenous
mixtures in water could not be prepared for these 2 test
materials.) Similarly, taking into account that tear fluid
is protein-rich [68], future research might aim at ad-
dressing if a higher dispersibility of NMs by preparing
test material suspensions in protein-containing media
changes the outcome of the BCOP assay.
Conclusion
All dry-powder NMs were consistently assessed as lack-
ing eye irritation potential in both the in vitro EpiOcu-
lar™–EIT and the BCOP assay. This outcome of the
present study is supported by available in vivo eye irrita-
tion data (noting that for most test materials in vivo data
were only available from nanosized or bulk materials of
the same composition). Nevertheless, due to the scien-
tific limitations of the in vivo eye irritation test, also dis-
cordant outcomes between the in vivo rabbit eye
irritation test and the in vitro testing strategy would not
necessarily preclude the applicability of the EpiOcular™-
EIT or BCOP assay.
Only two suspended NMs (Ag NM-300 K and aSiO2-
susp), were tested in the present study, and Ag NM-300 K
revealed eye irritation potential in Tier 1 (EpiOcular™-
EIT). It was not possible to determine whether this mater-
ial preparation has a potential for serious or irreversible
eye irritation potential in Tier 2 (BCOP assay), but upon
histopathological evaluation dark-brown patches were ob-
served on the surface of the treated corneas. The dispers-
ant of Ag NM-300 K alone (that does not contain silver
nanoparticles) yielded inconclusive results. In the in vivo
studies recorded in the REACH dossier for silver, dry-
powder Ag NMs did not produce ocular effects, whereas
Ag NMs suspended in an aqueous solution elicited min-
imal and fully reversible conjunctival redness in single ani-
mals only. Persistent corneal discolouration, which would
lead to substance classification as ‘serious eye damage, was
also not recorded in these in vivo studies.
Based upon the outcome of the present study, the 2-
tier EpiOcular™ – BCOP eye irritation testing strategy
appears promising to identify ‘Non-category’ dry-powder
NMs, whereas a final conclusion on its applicability for
NMs provided as suspensions is limited by the small
number of suspended NMs tested. Of the three suspended
test materials (2 of which being NMs), aSiO2-susp was
non-irritating in both in vitro tests; Ag NM-300 K was
assessed as ‘Category 1 or 2’ in the EpiOcular™-EIT and as
‘un-evaluable’ in the BCOP assay; Ag NM-300 K DIS was
assessed as ‘non-Category 1 or 2’ in the EpiOcular™-EIT
and as borderline positive (and ‘inconclusive’ due to high
inter-assay variability) in the BCOP assay. These test re-
sults highlight that further investigations are necessary to
develop a BCOP test protocol that is suitable for the
evaluation of suspended NMs. Only once such an adapted
test protocol is available, applicability of the BCOP assay
within a 2-tier (bottom-up or top-down) testing strategy
as full replacement of the in vivo eye irritation test can be
substantiated. However, this goal is further impeded by
the fact that reliable in vivo eye irritation data for a com-
prehensive set of NMs that would permit direct in vitro-in
vivo comparisons of NM eye irritation potential are
unavailable. Of note, also for dry-powder NMs, due to the
overall low or lacking in vitro or in vivo eye irritation po-
tential of the applied test materials, a conclusion on the
applicability of the 2-tier testing strategy to differentiate
between ‘Category 1’ and ‘Category 2’ NMs is not possible.
The selected panel of OECD representative NMs and
organic pigments did not cover the spectrum of possible
in vivo (or in vitro) eye irritating effects. To allow for a
comprehensive evaluation of the 2-tier EpiOcular™ –
BCOP eye irritation testing strategy, so-called benchmark
NMs are required, i.e. NMs which have been tested and
evaluated according to standard criteria and to which new
materials may reliably be compared [57, 69]. Accordingly,
comparative assessment of benchmark NMs with known
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in vivo ‘Category 1’ or ‘Category 2’ eye irritating effects –
provided that NMs were determined that possess such ef-
fects – would allow assessing the predictivity of the two in
vitro test methods, i.e. the EpiOcular™-EIT and BCOP
assay for NM eye irritation testing. Keeping this limitation
in mind, the outcome of the present study does indicate
that the tested dry-powder representative OECD NMs do
not have an eye irritation potential.
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